department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Erasca, Inc. ($ERAS) · pharmadog

PUBLIC COMPANY

$ERASErasca, Inc.

San Diego, CA, USupdated 50m ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

1

marketed

0

phase 3

0

catalysts ytd

1

approvals ytd

0

recalls ytd

0

Pipeline(1)

pipeline depth1 products

1Phase 1

Upcoming

no upcoming catalysts on record

Recent(90d)

earnings (1)

view all catalysts →

🐶 Hiring Signal

4 open roles at Erasca, Inc. →

Where Erasca, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.

therapeutic areaOncology 4

departmentClinical 2 Commercial 1 Manufacturing / CMC 1

News

no news has mentioned this company yet

identifiers

ticker

$ERAS

SEC CIK

0001761918

country

US

source

sec_tickers

top tags

mentioned in

0news items

entity-linker matched

Erasca, Inc. earnings

$ERAS18.85+2.06%

Insider activity

source: SEC Form 4

open-market buys + sells

Apr 1, 26SELLGarner Ebun· Chief Legal Officer80,000 sh @ $16.40−$1.31M↗
Mar 4, 26SELLMorris Shannon· Chief Medical Officer20,000 sh @ $15.04−$301K↗

routine RSU / option mechanics (6)

Apr 1, 26option exerciseGarner Ebun · Chief Legal Officer80,000 sh
Apr 1, 26option exerciseGarner Ebun · Chief Legal Officer80,000 sh
Mar 4, 26option exerciseMorris Shannon · Chief Medical Officer20,000 sh
Jan 29, 26grantGarner Ebun · General Counsel & Corp. Sec.560,000 sh
Jan 29, 26grantLim Jonathan E · Chairman & CEO2,000,000 sh
Jan 29, 26grantChacko David M. · CFO and CBO640,000 sh

Active trials

phase1A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumorsactive not recruitingn=90
phase2A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignanciescompletedn=101
phase3A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)active not recruitingn=78
phase1A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutationsactive not recruitingn=86
phase1A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

recruiting

n=200

phase1A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumorsrecruitingn=200

phase2A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumorsactive not recruitingn=200

phase1A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLCcompletedn=24

more trials →

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 31m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

$ERAS18.85+2.06%